Nuvation Bio Inc. is a biopharmaceutical company. It engages in developing differentiated and novel therapeutic candidates for unmet needs in oncology. Nuvation Bio Inc., formerly known as Panacea Acquisition Corp., is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $7.87M |
| Net Income (Most Recent Fiscal Year) | $-567.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 70.18 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -5534.21% |
| Net Margin (Trailing 12 Months) | -5534.21% |
| Return on Equity (Trailing 12 Months) | -44.14% |
| Return on Assets (Trailing 12 Months) | -32.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 9.01 |
| Quick Ratio (Most Recent Fiscal Quarter) | 9.01 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 2620.57 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.23 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.16 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.37 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.35 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 340.26M |
| Free Float | 238.42M |
| Market Capitalization | $768.99M |
| Average Volume (Last 20 Days) | 4.00M |
| Beta (Past 60 Months) | 1.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 29.93% |
| Percentage Held By Institutions (Latest 13F Reports) | 61.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |